These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 4837176)

  • 21. [Hemochromatosis (hereditary, "primary" hemochromatosis)].
    Krayenbühl P; Naumann UK; Käser L; Vetter W
    Praxis (Bern 1994); 2007 Dec; 96(51-52):2029-35; quiz 2036-7. PubMed ID: 18217648
    [No Abstract]   [Full Text] [Related]  

  • 22. Hyperpigmentation and secondary hemochromatosis: a novel treatment with extracorporeal chelation.
    Held JL; Yankiver B; Kohn SR
    J Am Acad Dermatol; 1993 Feb; 28(2 Pt 1):253-4. PubMed ID: 8432923
    [No Abstract]   [Full Text] [Related]  

  • 23. Change in the thyroid function by use of deferoxamine in a patient with hemochromatosis complicated by hyperthyroidism.
    Kubota K; Kurabayashi H; Tamura J; Kawada E; Tamura K; Nagashima K; Shirakura T
    J Med; 1992; 23(1):75-7. PubMed ID: 1573342
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Desferrioxamine therapy induces clearance of iron deposits after bone marrow transplantation for thalassemia: case report.
    Giardini C; La Nasa G; Contu L; Galimberti M; Polchi P; Angelucci E; Baronciani D; Barbanti I; Muretto P; Lucarelli G
    Bone Marrow Transplant; 1993; 12 Suppl 1():108-10. PubMed ID: 8374548
    [No Abstract]   [Full Text] [Related]  

  • 25. Hemochromatosis and vitamin C.
    Herbert V
    Ann Intern Med; 1999 Sep; 131(6):475-6. PubMed ID: 10498572
    [No Abstract]   [Full Text] [Related]  

  • 26. Cardiac hemochromatosis.
    Templin C; Pertschy S; Schaefer A
    Int J Cardiol; 2007 Apr; 116(3):e109-10. PubMed ID: 17134777
    [No Abstract]   [Full Text] [Related]  

  • 27. [Long-term efficacy of subcutaneous administration of deferoxamine in patients with secondary hemochromatosis].
    Kobayashi M; Yano K; Fujisawa S
    Rinsho Ketsueki; 1996 Apr; 37(4):303-10. PubMed ID: 8847800
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [First results of a new iron chelating agent in the treatment of post-transfusional hemochromatosis].
    Giraud P; Orsini A; Giraud F; Pinsard N
    Arch Fr Pediatr; 1965 Apr; 22(4):463-8. PubMed ID: 5826583
    [No Abstract]   [Full Text] [Related]  

  • 29. Desferal therapy in iron storage disease.
    Thompson RB; Owen DM; Bell WN
    Am J Med Sci; 1967 Apr; 253(4):453-60. PubMed ID: 6021380
    [No Abstract]   [Full Text] [Related]  

  • 30. Intramuscular deferoxamine in hereditary hemochromatosis.
    Polo-Romero FJ
    Am J Hematol; 2006 Mar; 81(3):225-6. PubMed ID: 16493613
    [No Abstract]   [Full Text] [Related]  

  • 31. [Hemochromatosis].
    Darnis F
    Nouv Presse Med; 1972 Jan; 1(3):159-62. PubMed ID: 5061525
    [No Abstract]   [Full Text] [Related]  

  • 32. Hepatic cirrhosis and hemochromatosis in three horses.
    Pearson EG; Hedstrom OR; Poppenga RH
    J Am Vet Med Assoc; 1994 Apr; 204(7):1053-6. PubMed ID: 8045806
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Type 3 hemochromatosis and beta-thalassemia trait.
    Riva A; Mariani R; Bovo G; Pelucchi S; Arosio C; Salvioni A; Vergani A; Piperno A
    Eur J Haematol; 2004 May; 72(5):370-4. PubMed ID: 15059075
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Mechanism of action of desferrioxamine].
    Kaszewska-Jablońska I; Zielińska W
    Wiad Lek; 1975 Jan; 28(2):89-96. PubMed ID: 1111247
    [No Abstract]   [Full Text] [Related]  

  • 35. [Hemochromatosis of the heart].
    Scieszka J; Kalina Z; Knap J
    Kardiol Pol; 1990; 33(11-2):71-6. PubMed ID: 2096256
    [No Abstract]   [Full Text] [Related]  

  • 36. [Hemochromatosis (apropos of 100 cases)].
    Darnis F
    Ann Biol Clin (Paris); 1972; 30(4):349-78. PubMed ID: 5082971
    [No Abstract]   [Full Text] [Related]  

  • 37. Haemochromatosis in a case of thalassaemia haemoglobin E disease presenting with cirrhosis of liver.
    Mitra R; Sarkar S; Ganguli S; De BK
    J Indian Med Assoc; 1996 Jan; 94(1):29-30. PubMed ID: 8776041
    [No Abstract]   [Full Text] [Related]  

  • 38. Improvement in Left Ventricular Function Despite No Change in T2* with Iron Chelation in Secondary Hemochromatosis.
    Nijjar PS; Vongooru H; Tamene A; Valeti U; Masri C
    Minn Med; 2015 Jul; 98(7):47. PubMed ID: 26267924
    [No Abstract]   [Full Text] [Related]  

  • 39. [Idiopathic hemochromatosis. Therapeutics].
    Pergola F
    Presse Med (1893); 1967 May; 75(24):1221-2. PubMed ID: 4960744
    [No Abstract]   [Full Text] [Related]  

  • 40. [Myocardiopathy caused by iron deposition. Treatment with chelating agents].
    Rodríguez Reguero JJ; Iglesias Cubero G; Espolita Santos A; López de la Iglesia JM; Enríquez Martín J; Tomás Mauri J; López-Negrete L
    Rev Esp Cardiol; 1985; 38(5):356-7. PubMed ID: 4081244
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.